- Home
- NCV vs MAZE Comparison
NCV vs MAZE Comparison
Compare NCV & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- MAZE
- Stock Information
- Founded
- NCV 2003
- MAZE 2018
- Country
- NCV United States
- MAZE United States
- Employees
- NCV N/A
- MAZE N/A
- Industry
- NCV Finance Companies
- MAZE
- Sector
- NCV Finance
- MAZE
- Exchange
- NCV Nasdaq
- MAZE NYSE
- Market Cap
- NCV 317.4M
- MAZE 367.0M
- IPO Year
- NCV N/A
- MAZE 2025
- Fundamental
- Price
- NCV $14.20
- MAZE $11.50
- Analyst Decision
- NCV
- MAZE Strong Buy
- Analyst Count
- NCV 0
- MAZE 3
- Target Price
- NCV N/A
- MAZE $25.67
- AVG Volume (30 Days)
- NCV 405.1K
- MAZE 104.7K
- Earning Date
- NCV 01-01-0001
- MAZE 08-14-2025
- Dividend Yield
- NCV 12.48%
- MAZE N/A
- EPS Growth
- NCV N/A
- MAZE N/A
- EPS
- NCV N/A
- MAZE 0.34
- Revenue
- NCV N/A
- MAZE $167,500,000.00
- Revenue This Year
- NCV N/A
- MAZE N/A
- Revenue Next Year
- NCV N/A
- MAZE N/A
- P/E Ratio
- NCV N/A
- MAZE $34.28
- Revenue Growth
- NCV N/A
- MAZE N/A
- 52 Week Low
- NCV $2.84
- MAZE $6.71
- 52 Week High
- NCV $3.59
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- NCV 73.43
- MAZE N/A
- Support Level
- NCV $14.01
- MAZE N/A
- Resistance Level
- NCV $14.33
- MAZE N/A
- Average True Range (ATR)
- NCV 0.15
- MAZE 0.00
- MACD
- NCV 0.04
- MAZE 0.00
- Stochastic Oscillator
- NCV 85.23
- MAZE 0.00
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.